Key facts
- Orthofuse’s last known valuation is $8.3M (Dec 2025).
- It has raised $3.0M; the latest was Seed Round ($3.0M) in Dec 2025.
- Notable investors include Cambridge Angels, ACF Investors, Empirical Ventures, Didier Cowling, MedTech SuperConnector — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Orthofuse
- ·The full record, as it builds
Funding rounds
No funding rounds for Orthofuse are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Orthofuse
Developer of orthopedic implants designed to improve procedure reversibility, simplify surgical workflows, and enhance patient outcomes in complex surgical cases. The company offers implants manufactured using additive manufacturing and novel implant architectures that reduce surgical steps while maintaining strong fixation, enabling orthopedic surgeons and healthcare providers to perform procedures more efficiently and improve surgical outcomes.
- Sector
- Healthcare
- HQ
- Surrey, United Kingdom
- Founded
- 2024
- Employees
- 4
- Website
- orthofuse.co.uk/
- Ownership
- Privately Held (backing)
Orthofuse doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Orthofuse shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Orthofuse in its N-PORT filings yet. We sweep new filings monthly.